Supplemental_NN
financial_JJ
information_NOMZ
Summary_NN
of_PIN
differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
unaudited_JJ
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
adjustments_NOMZ
to_PIN
the_DT
groups_NN
net_JJ
income_NN
and_PHC
shareholders_NN
equity_NOMZ
of_PIN
applying_VBG
the_DT
significant_JJ
differences_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
._.
These_DEMP
are_VPRT [PASS]
summarised_VBN
in_PIN
the_DT
tabular_JJ
reconciliation_NOMZ
statements_NOMZ
set_VBN [WZPAST]
out_PIN
below_PLACE
._.
Reconciliation_NOMZ
of_PIN
consolidated_JJ
net_JJ
income_NN
Notes_NN
12_CD
months_NN
to_PIN
12_CD
months_NN
to_PIN
31_CD
Dec_NN
2003_CD
31_CD
Dec_NN
2002_CD
m_FW
m_FW
Profit_NN
attributable_JJ
to_PIN
shareholders_NN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
116_CD
179_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
i_FPP1
Business_NOMZ
combinations_NOMZ
36_CD
114_CD
iii_FW
Disposal_NN
of_PIN
investment_NOMZ
in_PIN
Nycomed_NN
Pharma_NN
-_:
1_CD
iv_NN
Derivative_JJ
hedging_GER
3_CD
66_CD
v_NN
Pension_NN
and_PHC
post_NN
retirement_NOMZ
costs_NN
15_CD
5_CD
vi_FW
Revenue_NN
recognition_NOMZ
1_CD
1_CD
vii_FW
Deferred_JJ
taxation_NOMZ
application_NOMZ
of_PIN
full_JJ
liability_NOMZ
method_NN
3_CD
6_CD
viii_FW
Compensated_VBN
absences_NN
,_,
equity_NOMZ
instruments_NOMZ
and_CC
other_JJ
7_CD
-_:
Tax_NN
effect_NN
of_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
30_CD
30_CD
x_SYM
Minority_NOMZ
interest_NN
-_:
1_CD
Total_JJ
US_FPP1
GAAP_NN
adjustments_NOMZ
27_CD
18_CD
Net_JJ
income_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
89_CD
161_CD
Basic_JJ
net_JJ
income_NN
per_PIN
share_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
12.7_CD
p_NN
23.4_CD
p_VPRT
Diluted_JJ
net_JJ
income_NN
per_PIN
share_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
12.6_CD
p_NN
23.3_CD
p_NN
Reconciliation_NOMZ
of_PIN
shareholders_NN
equity_NOMZ
Notes_NN
31_CD
Dec_NN
2003_CD
31_CD
Dec_NN
2002_CD
m_NN
m_NN
Equity_NOMZ
shareholders_NN
funds_NN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
1,240_CD
1,172_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
i_FPP1
Business_NOMZ
combinations_NOMZ
1,016_CD
1,067_CD
ii_FW
41_CD
Accounting_GER
for_PIN
investment_NOMZ
in_PIN
NMP_NN
42_CD
iv_NN
Derivative_JJ
hedging_GER
25_CD
33_CD
v_NN
Pension_NN
and_PHC
post_NN
retirement_NOMZ
costs_NN
46_CD
69_CD
vi_FW
Revenue_NN
recognition_NOMZ
3_CD
4_CD
vii_FW
Deferred_JJ
taxation_NOMZ
application_NOMZ
of_PIN
full_JJ
liability_NOMZ
method_NN
27_CD
28_CD
viii_NN
Compensated_VBN
absences_NN
,_,
equity_NOMZ
instruments_NOMZ
and_CC
other_JJ
21_CD
22_CD
ix_NN
Ordinary_JJ
dividend_NN
42_CD
36_CD
Tax_NN
effect_NN
of_PIN
US_FPP1
GAAP_NN
adjustments_NOMZ
113_CD
143_CD
Total_JJ
US_FPP1
GAAP_NN
adjustments_NOMZ
968_CD
968_CD
Shareholders_NN
equity_NOMZ
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
2,208_CD
2,140_CD
i_FPP1
Business_NOMZ
combinations_NOMZ
Under_IN
both_DT
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
,_,
acquisitions_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
purchase_NN
business_NOMZ
combinations_NOMZ
._.
However_CONJ
,_,
certain_JJ
differences_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
in_PIN
the_DT
application_NOMZ
of_PIN
the_DT
purchase_NN
method_NN
of_PIN
accounting_GER
for_PIN
business_NOMZ
combinations_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
Both_DT
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
require_VPRT [SUAV]
purchase_NN
consideration_NOMZ
to_TO
be_VB [PASS]
allocated_VBN
to_PIN
the_DT
net_JJ
assets_NN
acquired_VBN [WZPAST]
at_PIN
their_TPP3
fair_JJ
value_NN
on_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
,_,
with_PIN
the_DT
difference_NN
between_PIN
the_DT
consideration_NOMZ
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
identifiable_JJ
net_JJ
assets_NN
recorded_VBN
as_IN
goodwill_NN
._.
Under_IN
the_DT
requirements_NOMZ
of_PIN
Financial_NN
Reporting_GER
Standard_NN
FRS_NN
10_CD
Goodwill_NN
and_CC
intangible_JJ
assets_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
of_PIN
subsidiaries_NN
,_,
joint_JJ
ventures_NN
,_,
and_ANDC
associates_NN
during_PIN
accounting_GER
periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
after_IN
23_CD
December_NN
1998_CD
should_NEMD
be_VB [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
its_PIT
useful_JJ
economic_JJ
life_NN
._.
This_DEMO
treatment_NOMZ
of_PIN
goodwill_NN
is_VPRT [BEMA]
similar_PRED
to_PIN
its_PIT
treatment_NOMZ
under_IN
US_FPP1
GAAP_NN
prior_RB
to_PIN
the_DT
introduction_NOMZ
of_PIN
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Standards_NN
SFAS_NN
142_CD
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
._.
However_CONJ
,_,
because_CAUS
FRS_NN
10_CD
need_MD
not_XX0
be_VB [PASS]
applied_VBN
retrospectively_RB
to_PIN
goodwill_NN
written_VBN [PUBV] [WZPAST]
off_PIN
against_PIN
shareholders_NN
funds_NN
in_PIN
earlier_TIME
years_NN
,_,
there_EX
will_PRMD
continue_VB
to_TO
be_VB
differences_NN
between_PIN
the_DT
goodwill_NN
calculated_VBN [PRIV]
under_IN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
._.
For_PIN
the_DT
purposes_NN
of_PIN
US_FPP1
GAAP_NN
,_,
goodwill_NN
written_VBN [PUBV] [WZPAST]
off_PIN
against_PIN
shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
has_VPRT [PEAS]
been_VBN [PASS]
reinstated_VBN
._.
72_CD
UK_NN
GAAP_NN
requires_VPRT [SUAV]
an_DT
allocation_NOMZ
of_PIN
purchase_NN
consideration_NOMZ
to_PIN
intangible_JJ
assets_NN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
separable_PRED
from_PIN
the_DT
business_NOMZ
._.
For_PIN
UK_NN
GAAP_NN
purposes_NN
,_,
intangible_JJ
assets_NN
,_,
other_JJ
than_PIN
goodwill_NN
,_,
acquired_VBN [PASTP]
in_PIN
a_DT
business_NOMZ
combination_NOMZ
,_,
which_WDT [SERE]
are_VPRT [BEMA]
not_XX0
separable_PRED
and_PHC
measurable_PRED
,_,
are_VPRT [PASS]
not_XX0
capitalized_VBN
._.
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
an_DT
allocation_NOMZ
of_PIN
consideration_NOMZ
to_PIN
identifiable_JJ
intangible_JJ
assets_NN
if_COND
they_TPP3
arise_VPRT
from_PIN
contractual_JJ
or_CC
other_JJ
legal_JJ
rights_NN
:_:
if_COND
intangible_JJ
assets_NN
do_VPRT
not_XX0
arise_VB
from_PIN
contractual_JJ
or_CC
legal_JJ
rights_NN
,_,
the_DT
asset_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
apart_RB
from_PIN
goodwill_NN
only_DWNT
if_COND
it_PIT
is_VPRT [BEMA]
separable_PRED
._.
The_DT
intangible_JJ
assets_NN
recognized_VBN [PRIV] [WZPAST]
for_PIN
US_FPP1
GAAP_NN
are_VPRT
being_VBG [PASS]
amortised_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
periods_NN
up_IN
to_PIN
15_CD
years_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
following_VBG [PRESP]
the_DT
introduction_NOMZ
of_PIN
SFAS_NN
142_CD
,_,
goodwill_NN
and_CC
intangible_JJ
assets_NN
with_PIN
indefinite_JJ
useful_JJ
lives_NN
are_VPRT [PASS]
not_XX0
amortised_VBN
but_CC
reviewed_VBN
annually_RB
for_PIN
impairment_NOMZ
._.
The_DT
annual_JJ
goodwill_NN
amortisation_NOMZ
charge_NN
recognized_VBN [PRIV] [WZPAST]
for_PIN
UK_NN
GAAP_NN
has_VPRT [SPAU] [PEAS]
therefore_CONJ
been_VBN [PASS]
reversed_VBN
for_PIN
US_FPP1
GAAP_NN
purposes_NN
._.
Purchase_NN
of_PIN
45_CD
%_NN
minority_NOMZ
interest_NN
in_PIN
Amersham_NN
Biosciences_NN
in_PIN
2002_CD
Under_IN
UK_NN
GAAP_NN
,_,
fair_JJ
value_NN
adjustments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
for_PIN
tangible_JJ
fixed_JJ
assets_NN
,_,
listed_VBN
investments_NOMZ
and_CC
the_DT
funded_JJ
status_NN
of_PIN
pensions_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
additional_JJ
fair_JJ
value_NN
adjustments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
for_PIN
separable_JJ
intangible_JJ
assets_NN
,_,
in-process_JJ
research_NN
and_PHC
development_NOMZ
and_CC
the_DT
revaluation_NOMZ
of_PIN
inventory_NN
._.
Intangible_JJ
assets_NN
are_VPRT
being_VBG [PASS]
amortised_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
periods_NN
up_IN
to_PIN
10_CD
years_NN
._.
Profit_NN
or_CC
loss_NN
on_PIN
the_DT
partial_JJ
disposal_NN
of_PIN
businesses_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
gains_VPRT
on_PIN
the_DT
partial_JJ
disposal_NN
of_PIN
businesses_NOMZ
involving_VBG [WZPRES]
non-monetary_JJ
consideration_NOMZ
are_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
when_RB
recorded_VBN
in_PIN
connection_NOMZ
with_PIN
a_DT
business_NOMZ
combination_NOMZ
,_,
these_DEMO
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
ii_FW
Accounting_GER
for_PIN
investment_NOMZ
in_PIN
Nihon_NN
Medi-Physics_NN
NMP_NN
Under_IN
UK_NN
GAAP_NN
the_DT
change_NN
from_PIN
the_DT
cost_NN
method_NN
to_PIN
the_DT
equity_NOMZ
method_NN
in_PIN
the_DT
year_NN
ended_VBD
31_CD
March_NN
1997_CD
,_,
due_JJ
to_PIN
the_DT
acquisition_NOMZ
of_PIN
an_DT
additional_JJ
interest_NN
in_PIN
NMP_NN
,_,
did_VBD
not_XX0
require_VB [SUAV]
retroactive_JJ
adjustment_NOMZ
to_PIN
the_DT
financial_JJ
statements_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
investment_NOMZ
,_,
the_DT
results_NN
of_PIN
operations_NOMZ
,_,
and_ANDC
shareholders_NN
equity_NOMZ
of_PIN
the_DT
group_NN
were_VBD [PASS]
adjusted_VBN
retroactively_RB
in_PIN
a_DT
manner_NN
consistent_JJ
with_PIN
the_DT
accounting_GER
for_PIN
a_DT
step-by-step_JJ
acquisition_NOMZ
of_PIN
a_DT
subsidiary_NN
._.
iii_FW
Disposal_NN
of_PIN
investment_NOMZ
in_PIN
Nycomed_NN
Pharma_NN
In_PIN
2001_CD
,_,
the_DT
group_NN
sold_VBD
its_PIT
trade_NN
investment_NOMZ
in_PIN
Nycomed_NN
Pharma_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
investment_NOMZ
was_VBD [PASS]
treated_VBN
as_IN
an_DT
associate_JJ
company_NN
resulting_VBG [WZPRES]
in_PIN
a_DT
lower_JJ
profit_NN
on_PIN
disposal_NN
under_IN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
._.
Certain_JJ
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
sale_NN
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
2002_CD
for_PIN
US_FPP1
GAAP_NN
._.
iv_NN
Derivative_JJ
hedging_GER
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
group_NN
does_VPRT
not_XX0
qualify_VB
for_PIN
hedge_JJ
accounting_GER
and_CC
so_RB
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
on_PIN
derivative_JJ
instruments_NOMZ
at_PIN
the_DT
year_NN
end_NN
have_VPRT [PEAS]
been_VBN [PASS]
booked_VBN
directly_RB
to_PIN
income_NN
._.
v_FW
Pension_NN
and_PHC
post_NN
retirement_NOMZ
costs_NN
Under_IN
both_DT
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
,_,
pension_NN
and_PHC
post_NN
retirement_NOMZ
costs_NN
are_VPRT [PASS]
based_VBN
on_PIN
actuarial_JJ
assumptions_NOMZ
._.
However_CONJ
,_,
under_IN
UK_NN
GAAP_NN
the_DT
cost_NN
is_VPRT [PASS]
based_VBN
on_PIN
long_JJ
term_NN
market_NN
and_CC
economic_JJ
assumptions_NOMZ
and_CC
under_IN
US_FPP1
GAAP_NN
the_DT
cost_NN
is_VPRT [PASS]
based_VBN
on_PIN
current_JJ
market_NN
and_CC
economic_JJ
assumptions_NOMZ
._.
In_PIN
line_NN
with_PIN
SFAS_NN
87_CD
Employers_NN
Accounting_GER
for_PIN
Pensions_NN
an_DT
additional_JJ
minimum_NN
liability_NOMZ
equal_JJ
to_PIN
the_DT
unfunded_JJ
accumulated_VBN
benefit_NN
obligation_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
accumulated_VBN
benefit_NN
obligation_NOMZ
exceeds_VPRT
the_DT
fair_JJ
value_NN
of_PIN
pension_NN
fund_NN
assets_NN
._.
A_DT
transfer_NN
of_PIN
assets_NN
was_VBD [PASS]
received_VBN
from_PIN
former_JJ
pension_NN
plans_NN
during_PIN
2001_CD
._.
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
proportion_NOMZ
of_PIN
the_DT
transfer_NN
relating_VBG [WZPRES]
to_PIN
current_JJ
employees_NN
of_PIN
the_DT
group_NN
is_VPRT
being_VBG [PASS]
spread_VBN
over_IN
the_DT
remaining_VBG
service_NN
life_NN
of_PIN
the_DT
employees_NN
in_PIN
line_NN
with_PIN
SSAP_NN
24_CD
._.
Under_IN
US_FPP1
GAAP_NN
this_DEMP
was_VBD [PASS]
taken_VBN
to_PIN
income_NN
during_PIN
2001_CD
._.
vi_FW
Revenue_NN
recognition_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
contract_NN
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
it_PIT
is_VPRT [PASS]
earned_VBN
and_CC
non-refundable_JJ
and_ANDC
when_RB
there_EX
are_VPRT
no_SYNE
future_JJ
obligations_NOMZ
under_IN
the_DT
contract_NN
terms_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
group_NN
applies_VPRT
Staff_NN
Accounting_GER
Bulletin_NN
101_CD
SAB_NN
101_CD
Revenue_NN
Recognition_NOMZ
in_PIN
Financial_NN
Statements_NOMZ
._.
Under_IN
SAB_NN
101_CD
,_,
more_EMPH
prescriptive_JJ
criteria_NN
are_VPRT [PASS]
applied_VBN
to_TO
assess_VB
whether_IN
the_DT
culmination_NOMZ
of_PIN
the_DT
earnings_GER
process_NN
has_VPRT [PEAS]
occurred_VBN
and_CC
the_DT
group_NN
has_VPRT
a_DT
continuing_VBG
obligation_NOMZ
throughout_PIN
the_DT
contract_NN
terms_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
certain_JJ
non-refundable_JJ
fees_NN
have_VPRT [PEAS]
been_VBN [PASS]
deferred_VBN
over_IN
the_DT
contract_NN
terms_NN
under_IN
US_FPP1
GAAP_NN
._.
73_CD
vii_FW
Deferred_JJ
taxation_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
provision_NN
for_PIN
deferred_VBN
taxation_NOMZ
is_VPRT [PASS]
recorded_VBN
under_IN
FRS_NN
19_CD
._.
Except_PIN
for_PIN
certain_JJ
timing_NN
differences_NN
relating_VBG [WZPRES]
to_PIN
revaluations_NOMZ
,_,
rolled_VBD
over_IN
taxable_JJ
gains_NN
and_CC
unremitted_JJ
income_NN
,_,
a_DT
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
all_QUAN
timing_NN
differences_NN
that_TSUB
would_PRMD
give_VB
rise_VB
to_PIN
a_DT
deferred_VBN
tax_NN
liability_NOMZ
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
they_TPP3
will_PRMD
be_VB [BEMA]
recoverable_PRED
._.
Under_IN
US_FPP1
GAAP_NN
,_,
deferred_VBN
tax_NN
is_VPRT [PASS]
provided_VBN
for_PIN
on_PIN
a_DT
full_JJ
liability_NOMZ
basis_NN
,_,
which_WDT [SERE]
includes_VPRT
these_DEMO
exceptions_NOMZ
noted_VBD [PRIV]
above_PLACE
._.
A_DT
valuation_NOMZ
allowance_NN
is_VPRT [PASS]
established_VBN [PRIV]
when_RB [WHCL]
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
some_QUAN
portion_NOMZ
or_CC
all_QUAN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
will_PRMD
not_XX0
be_VB [PASS]
realized_VBN [PRIV]
._.
viii_FW
Compensated_VBN
absences_NN
,_,
equity_NOMZ
instruments_NOMZ
and_CC
other_JJ
Differences_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
relate_VPRT
to_TO
accounting_VBG
for_PIN
compensated_VBN
absences_NN
,_,
investments_NOMZ
in_PIN
equity_NOMZ
securities_NOMZ
,_,
ESOP_NN
transactions_NOMZ
,_,
social_JJ
security_NOMZ
on_PIN
share_NN
option_NOMZ
gains_NN
and_PHC
stock_NN
based_VBN
compensation_NOMZ
._.
ix_FW
Ordinary_NN
dividends_NN
Under_IN
UK_NN
GAAP_NN
,_,
dividends_NN
proposed_VBN [SUAV] [WZPAST]
are_VPRT [PASS]
provided_VBN
for_PIN
in_PIN
the_DT
period_NN
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [BYPA]
recommended_VBN [SUAV]
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
for_PIN
approval_NN
by_PIN
the_DT
shareholders_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
dividends_NN
are_VPRT [PASS]
recorded_VBN
as_IN
a_DT
reduction_NOMZ
to_TO
retained_VBN
earnings_GER
when_RB
they_TPP3
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
formally_RB
declared_VBN [PUBV]
,_,
and_ANDC
notice_VB [PRIV]
given_VBN
to_PIN
shareholders_NN
._.
x_LS
Minority_NOMZ
interest_NN
The_DT
amount_NN
represents_VPRT
the_DT
components_NN
of_PIN
the_DT
US_FPP1
GAAP_NN
adjustments_NOMZ
attributable_JJ
to_PIN
Pharmacia_NN
Corporations_NOMZ
45_CD
%_NN
interest_NN
in_PIN
Amersham_NN
Biosciences_NN
._.
The_DT
minority_NOMZ
interest_NN
was_VBD [PASS]
extinguished_VBN
in_PIN
2002_CD
on_PIN
the_DT
purchase_NN
of_PIN
the_DT
45_CD
%_NN
interest_NN
in_PIN
Amersham_NN
Biosciences_NN
that_TOBJ
the_DT
group_NN
did_VBD
not_XX0
already_RB
own_VB
._.
